The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

August 8, 2012 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

But Dr. Smolen suggested that more work needs to be done in this area, noting that comparative effectiveness research is something rheumatologists crave. He said that since it’s been found that a third of patients taking TNF-inhibitors don’t take them in conjunction with methotrexate or another biologic, as is generally suggested, more needs to be known about how they work as monotherapies.

You Might Also Like
  • EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
  • Drug Updates: EULAR 2012
  • California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis
Explore This Issue
August 2012
Also By This Author
  • 2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis

In the ADACTA study, subcutaneous tocilizumab was compared to subcutaneous adalimumab, with the results significantly favoring tocilizumab.11

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The emergence of biologics has raised still another question: When can they be withdrawn, if at all. Dr. Smolen said that the research has shown that it depends on the stage of the disease. “For established RA, it may not be wise to withdraw the biologic,” he said. “Overall, withdrawal in patients will lead to flares in the vast majority of the patients. This is different in early disease.”


Thomas Collins is a freelance medical writer based in Florida.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-975.
  2. Katchamart W, Bombardier C. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis. J Rheumatol. 2010;37:1411-1415.
  3. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-586.
  4. Saleem B, Brown AK, Quinn M, et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis. 2012 Jan 31. [Epub ahead of print]
  5. De Vera MA, Choi H, Abrahamowicz M, Kopec J, Goycochea-Robles MV, Lacaille D. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: A population-based cohort study. Ann Rheum Dis. 2011;70:1020-1024.
  6. de Jong HJ, Klungel OH, van Dijk L, et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis. 2012;71:648-654.
  7. Freeston JE, Wakefield RJ, Conaghan PG, Hensor EM, Stewart SP, Emery P. A diagnostic algorithm for persistence of very early inflammatory arthritis: The utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis. 2010;69:417-419.
  8. Nam JL, Villeneuve E, Hensor EMA, et al. Inhibition of structural damage with two intensive treatment strategies using infliximab or high dose intravenous steroid followed by treat to target in DMARD naïve rheumatoid arthritis (the IDEA study)—a preliminary report. Ann Rheum Dis. 2012;71(Suppl3):106.
  9. van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379:1712-1720.
  10. Schiff M, Fleischmann R, Weinblatt M, et al. Abatacept SC versus adalimumab on background methotrexate in RA: One year results from the ample study. Ann Rheum Dis. 2012;71(Suppl3):60.
  11. Gabay C, Emery P, van Vollenhoven R, et al, Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial. Ann Rheum Dis. 2012;71(Suppl3):152.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Guidelines, Meeting Reports, Rheumatoid Arthritis Tagged With: Biologics, EULAR, HYDROXYCHLOROQUINE, infliximab, International, Methotrexate, patient care, Rheumatoid arthritis, rheumatologist, tocilizumabIssue: August 2012

You Might Also Like:
  • EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
  • Drug Updates: EULAR 2012
  • California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis
  • EULAR 2012: Rewards in Risk Factor Research

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.